Circulating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study (CITCCA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04726800 |
Recruitment Status :
Active, not recruiting
First Posted : January 27, 2021
Last Update Posted : February 20, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Colorectal Cancer |
Study Type : | Observational |
Estimated Enrollment : | 300 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Pilot Study Investigating the Feasibility to Perform Prospective Circulating Tumor DNA (ctDNA) Profiling in Patients With Colorectal Cancer |
Actual Study Start Date : | October 1, 2020 |
Estimated Primary Completion Date : | December 2024 |
Estimated Study Completion Date : | December 2024 |
- Feasibility and logistics of measuring ctDNA [ Time Frame: 2 years ]
- Frequency of positive ctDNA postoperatively in relation to tumour stage and oncological outcome. [ Time Frame: 3 years ]
- Frequency of positive ctDNA preoperative converted to negative postoperatively. [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
Participants will be asked to donate 30ml blood before surgery (baseline), after surgery at 4-6 weeks, 3-, 6-, 12- and 24 months postoperatively to measure cell-free DNA (cfDNA) in plasma.
All biospecimens will be shipped to the biobank at Karolinska Institutet for further processing. DNA will be extracted from tumor tissue and whole blood. Targeted sequencing of tumor tissue and germline DNA will be performed using in solution hybridization-based capture at Clinical Genomics, SciLife Lab, Stockholm. Blood in the CITCCA pilot will be profiled prospectively with a two-week turnover, using the ProBio infrastructure, mimicking a real clinical scenario where minimal residual disease (MRD) information will be available in a condense report format.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Colon or rectal cancer tumor stage I-III planned for radical surgery
- Clean Colonoscopy or Computed Tomography (CT) colon within 3 months preoperatively or postoperatively but before randomization
- Patient able to understand and sign written informed consent
Exclusion Criteria:
- Distant metastases
- Other cancers (excluding colorectal cancer or other skin cancer than melanoma) within 3 years from screening
- Significant medical illness that would interfere with study participation
- Pregnancy or breastfeeding females
- Current participation in another clinical trial that will be in conflict with the present study
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude, inability to return for subsequent visits) and/or otherwise considered by the Investigator to be unlikely to complete the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04726800
Norway | |
Akershus Univeristy Hospital | |
Oslo, Norway | |
Sweden | |
Sahlgrenska University Hospital | |
Göteborg, Sweden | |
Skaraborg Hospital | |
Skövde, Sweden | |
Capio Sankt Göran Hospital | |
Stockholm, Sweden | |
Danderyd University Hospital | |
Stockholm, Sweden | |
Ersta Hospital | |
Stockholm, Sweden | |
Karolinska University Hospital | |
Stockholm, Sweden | |
South Hospital | |
Stockholm, Sweden |
Principal Investigator: | Anna Martling, Professor | Karolinska Institutet |
Responsible Party: | Anna Martling, Professor, Senior Consultant Surgeon, Karolinska Institutet |
ClinicalTrials.gov Identifier: | NCT04726800 |
Other Study ID Numbers: |
2019-04884 |
First Posted: | January 27, 2021 Key Record Dates |
Last Update Posted: | February 20, 2024 |
Last Verified: | February 2024 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
predictive marker prognostic marker ctDNA colon cancer rectal cancer |
Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |